Health Technology · Pharmaceuticals: Major · NSE: SAKAR · data 2026-10-09

Sakar Healthcare Ltd

Health check: Strong (6.7/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,011.5

Market cap

₹2,200 cr

P/E

62.3

P/B

—

ROE

10.0%

ROCE

12.4%

Debt / equity

0.17

Dividend yield

0.00%

1-year return

176.6%

52-week high

₹1,229.85

52-week low

₹345.5

Operating margin

19.4%

Growth

Revenue (last 12 months)	₹272 cr
Net profit (last 12 months)	₹36 cr
Sales growth, 3 years (yearly)	23.6%
Profit growth, 3 years (yearly)	33.7%

Chart patterns

Double bottom — breakout (key level ₹928)
Double top — breakdown (key level ₹1,042.7)

Similar companies

Venus Remedies Limited (VENUSREM) · Syncom Formulation (India) Ltd. (SYNCOMF) · Sai Parenterals Limited (SAIPARENT) · Indoco Remedies Limited (INDOCO) · Panacea Biotec Limited (PANACEABIO)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open SAKAR in NSE Scanner →